Infect And Treat
Infect And Treat - Related Videos
06:49
Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
0 Views •
Cited by 18 •
2014
Batrachochytrium dendrobatidis infection in amphibians can be eliminated using a reduced concentration (0.0025%) and shorter duration (five minute baths for six days) of itraconazole than is generally used. Less mortality and fewer negative side effects were observed using this modified treatment protocol.
04:19
Oral Combinational Antiretroviral Therapy to Treat HIV-1 Infection in a Humanized Mouse Model
0 Views •
2025
This video demonstrates an assay to evaluate the effectiveness of oral combined antiretroviral therapy (oral cART) in a human immunodeficiency virus-1 (HIV-1)-infected humanized mouse model. A combination of drugs targeting HIV-1, including nucleoside reverse transcriptase inhibitors and integrase strand transfer inhibitors, is administered along with a nutritional supplement and antibiotics. Following the consumption of this mixture by the humanized mice infected with HIV-1, the effective...
08:52
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
0 Views •
Cited by 49 •
2011
A rapid, simple and cost-effective protocol for the generation of donor-derived multivirus-specific CTLs (rCTL) for infusion to allogeneic hematopoietic stem cell transplant (HSCT) recipients at risk of developing CMV, Adv or EBV infections. This manufacturing process is GMP-compliant and should ensure the broader implementation of T-cell immunotherapy beyond specialized centers.
07:59
Bioluminescence Imaging to Detect Late Stage Infection of African Trypanosomiasis
0 Views •
Cited by 3 •
2016
This manuscript describes the use of a bioluminescent strain of African trypanosomes to enable the tracking of late stage infection and demonstrates how in vivo live imaging can be used to visualize infections within the central nervous system in real-time.
12:30
Use of Galleria mellonella as a Model Organism to Study Legionella pneumophila Infection
0 Views •
Cited by 108 •
2013
The larva of the wax moth Galleria mellonella was recently established as an in vivo model to study Legionella pneumophila infection. Here, we demonstrate fundamental techniques to characterize the pathogenesis of Legionella in the larvae, including inoculation, measurement of bacterial virulence and replication as well as extraction and analysis of infected hemocytes.
FAQs
Treatment timing determines which stage of the host–pathogen interaction is being assessed. Applying an intervention at a defined point after infection allows researchers to relate treatment effects to established infection rather than to initial exposure alone. Comparing outcomes across controlled timing conditions can clarify when treatment most strongly influences pathogen burden, cell viability, or immune responses.
A defined treatment dose makes comparisons between infected and treated groups interpretable. Changes in dose may alter the measured effects on pathogen burden, host-cell viability, or immune responses, so dose must be considered alongside treatment timing. This design helps researchers determine whether an intervention produces a measurable response under the selected experimental conditions.
Researchers can examine several outcomes rather than relying on a single measurement. Pathogen burden indicates the intervention’s effect on infection, while cell viability reflects effects on the host and immune-response measurements reveal changes in host defenses. Comparing these outcomes with untreated controls helps separate reduced infection from changes in host-cell or immune behavior.
The workflow begins by establishing infection in host cells, tissues, or organisms under controlled conditions. Researchers then apply an antimicrobial or other intervention at a defined time and dose, followed by measurement of selected outcomes. Untreated controls provide the reference needed to evaluate treatment-associated changes in pathogen burden, viability, and immune responses.
This approach is useful when researchers need to evaluate therapeutic efficacy while also examining host-pathogen interactions. It can show whether an intervention changes infection levels, affects host-cell viability, or modifies immune responses. These results help identify factors that influence treatment success and support the study of therapies directed at pathogens or host responses.
By comparing treated and untreated infection conditions, researchers can assess how interventions influence pathogen burden and host responses. The same framework supports investigations of drug resistance by testing treatment outcomes under controlled infection conditions. It also accommodates host-directed therapies, where the relevant outcome may include altered immune responses or improved host-cell viability rather than pathogen reduction alone.